- Home
- SHBI vs ORKA Comparison
SHBI vs ORKA Comparison
Compare SHBI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHBI
- ORKA
- Stock Information
- Founded
- SHBI 1876
- ORKA 2004
- Country
- SHBI United States
- ORKA United States
- Employees
- SHBI N/A
- ORKA N/A
- Industry
- SHBI Major Banks
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SHBI Finance
- ORKA Health Care
- Exchange
- SHBI Nasdaq
- ORKA Nasdaq
- Market Cap
- SHBI 532.0M
- ORKA 580.3M
- IPO Year
- SHBI N/A
- ORKA N/A
- Fundamental
- Price
- SHBI $17.00
- ORKA $16.00
- Analyst Decision
- SHBI Buy
- ORKA Strong Buy
- Analyst Count
- SHBI 1
- ORKA 8
- Target Price
- SHBI $20.00
- ORKA $40.43
- AVG Volume (30 Days)
- SHBI 116.1K
- ORKA 137.1K
- Earning Date
- SHBI 10-23-2025
- ORKA 08-11-2025
- Dividend Yield
- SHBI 2.83%
- ORKA N/A
- EPS Growth
- SHBI 169.45
- ORKA N/A
- EPS
- SHBI 1.61
- ORKA N/A
- Revenue
- SHBI $208,209,000.00
- ORKA N/A
- Revenue This Year
- SHBI N/A
- ORKA N/A
- Revenue Next Year
- SHBI $16.05
- ORKA N/A
- P/E Ratio
- SHBI $10.52
- ORKA N/A
- Revenue Growth
- SHBI 24.24
- ORKA N/A
- 52 Week Low
- SHBI $11.47
- ORKA $5.49
- 52 Week High
- SHBI $17.61
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- SHBI 58.33
- ORKA 57.22
- Support Level
- SHBI $16.87
- ORKA $15.52
- Resistance Level
- SHBI $17.22
- ORKA $16.21
- Average True Range (ATR)
- SHBI 0.31
- ORKA 0.88
- MACD
- SHBI -0.00
- ORKA 0.04
- Stochastic Oscillator
- SHBI 46.43
- ORKA 65.35
About SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.